

1 **Original article**

2

3 **Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus**
4 **dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast**
5 **cancer: A prospective pilot study**

6

7 **Authors:** Yu Zhang^{1,2,3,4†}, Shuo Cao^{1†}, Nan Niu^{1,2,3†}, Huilian Shan^{1†}, Jinqi Xue^{1,2,3†},
8 Guanglei Chen^{1,2,3}, Yongqing Xu¹, Jianqiao Yin¹, Chao Liu^{1,2,3}, Lisha Sun^{1,2,3}, Xiaofan
9 Jiang^{1,2,3}, Meiyue Tang¹, Qianshi Xu^{1,2}, Mingxuan Jia¹, Xu Zhang¹, Zhenyong Zhang¹,
10 Qingfu Zhang⁵, Jianfei Wang⁶, Ailin Li¹, Yongliang Yang^{7*}, Caigang Liu^{1,2,3*}

11

12 **Author Affiliations:**

13 ¹ Department of Oncology, Shengjing Hospital of China Medical University,
14 Shenyang, China;

15 ² Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of
16 China Medical University, Shenyang, China;

17 ³ Innovative Cancer Drug Research and Development Engineering Center of Liaoning
18 Province, Shenyang, China.;

19 ⁴ Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou
20 Medical University, Yantai, China;

21 ⁵ Department of Pathology, the First Affiliated Hospital and College of Basic Medical
22 Sciences of China Medical University, Shenyang, China;

23 ⁶ Jiangsu Hengrui Pharmaceuticals, Shanghai, China;

24 ⁷ School of Bioengineering, Dalian University of Technology, Dalian, China.

25 **Authors' contributions**

26 S. Cao, Data curation, formal analysis, methodology, writing—original draft. G. Chen,
27 Data curation, methodology. J. Xue, Data curation, methodology. N. Niu, Validation,
28 data curation, formal analysis, methodology, writing—review and editing. Y. Zhang:
29 Data curation, formal analysis, methodology. Y. Xu, Methodology. J. Yin,
30 Methodology. C. Liu, Formal analysis, methodology. L. Sun, Methodology. X. Jiang,
31 Writing-original draft. M. Tang, Data curation. Q. Xu, Formal analysis. M. Jia,
32 Methodology. X. Zhang, Methodology. Z. Zhang, Methodology. Q. Zhang, Formal
33 analysis. H. Li, Formal analysis. A. Li, Conceptualization, methodology. Y. Yang,
34 Methodology, writing—review and editing. Caigang Liu, Conceptualization,
35 supervision, project administration, writing—review and editing.

36 Shuo Cao, Yu Zhang, Jinqi Xue and Guanglei Chen contributed equally to this work.

37

38 **Corresponding author:**

39 Caigang Liu, MD, PhD

40 Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004,

41 China

42 Tel.: 86-18940254967

43 E-mail: liucg@sj-hospital.org

44

45

46

47

48

49 **Abstract**

50 **Background:** Both neoadjuvant chemotherapy and endocrine therapy only result in
51 trivial pathological complete response rates and moderate objective response rates
52 (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2
53 (HER2)-negative breast cancer, more promising alternatives are urgently needed.
54 With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor and
55 radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and
56 safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by
57 darpiciclib and exemestane in HR-positive, HER2-negative breast cancer.

58 **Methods:** This was a single-arm, non-controlled prospective pilot study. Treatment-
59 naïve patients with unilateral HR-positive, HER2-negative breast cancer received
60 neoadjuvant radiotherapy (24Gy/3F) followed by darpiciclib and exemestane for 6
61 cycles. The primary endpoint was the proportion of patients with residual cancer
62 burden (RCB) score of 0-I. Key secondary endpoints included ORR, biomarker
63 analysis, and safety.

64 **Results:** All 12 enrolled patients completed the study treatment and surgery. Two
65 (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of
66 tumor specimens showed significant increase of infiltrating T cells rather than

67 alteration of PD-L1 positive immune cells. The most common grade 3 adverse events
68 (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4-5 AE or
69 death occurred.

70 **Conclusions:** Our results suggested neoadjuvant SBRT followed by darpiciclib and
71 exemestane are effective and tolerable, and provides novel insights for the
72 neoadjuvant treatment of HR+/HER2- breast cancer, which may be considered as an
73 alternative to patients with HR-positive, HER2-negative breast cancer.

74

75

76 **Funding: None**

77

78 **Clinical trial number: NCT05132790**

79

80 **Impact statement: Neoadjuvant SBRT with darpiciclib and exemestane resulted**
81 **in a 16.7% RCB 0-I rate and a 91.7% ORR, with acceptable toxicities in HR-**
82 **positive, HER2-negative breast cancer patients.**

83 **Introduction**

84 Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-
85 negative breast cancer is the most prevalent subtype of breast cancer, which accounts
86 for approximately 70% of all breast cancer (Parker et al., 2009) . Neoadjuvant
87 chemotherapy (NCT) is recommended as the first-choice for patients with HR-
88 positive, HER2-negative breast cancer, who are candidates for preoperative therapy,
89 according to National Comprehensive Cancer Network (NCCN) guidelines(Gradishar
90 et al., 2022). Neoadjuvant endocrine therapy (NET) is an acceptable, less toxic
91 alternative of NCT. However, less than 10% of patients with HR-positive, HER2-
92 negative breast cancer can achieve pathological complete response (pCR), and only
93 60% of patients respond to NCT or NET (Sella et al., 2021) . Hence, more promising
94 alternatives are urgently needed.

95 Cyclin dependent kinase 4/6 (CDK4/6) inhibitors are breakthroughs in the treatment
96 of HR-positive, HER2-negative breast cancer, and have a remarkable efficacy in the
97 advanced setting when combined with endocrine therapy (ET) (Finn et al., 2015;
98 Goetz et al., 2017; Hortobagyi et al., 2016) . Presently, abemaciclib has been
99 approved for high-risk, early HR-positive breast cancer plus ET as adjuvant treatment
100 and its application is being explored in neoadjuvant setting (neoMONARCH and
101 NCT04293393). However, therapies with combination of CDK4/6 inhibitors and NET
102 only achieve a pCR rate of less than 5% (Hurvitz et al., 2020; Johnston et al.,
103 2019) .In the PALLET study, objective response rate (ORR) was not statistically

104 significantly different between the combinational therapy and monotherapy (54.3% vs
105 49.5%, $P = 0.20$) (Johnston et al., 2019) . Likewise, in the FELINE study, there was
106 no statistical difference in clinical, mammographic, ultrasound or magnetic resonance
107 imaging (MRI) response between letrozole alone and combination of letrozole with a
108 CDK4/6 inhibitor(Khan et al., 2020) . Thus, it is reasonable to explore a novel
109 neoadjuvant therapy for HR-positive, HER2-negative breast cancer.

110 Radiotherapy is one of the most important local methods to control malignancy by
111 breaking DNA in tumor cells (Cox & Swanson, 2013) . Stereotactic body radiation
112 therapy (SBRT) is a novel and relatively safe radiotherapy technique and delivers
113 high doses of radiation in a small number of fractions to the tumor lesion while
114 minimizing radiation exposure to the surrounding tissues(Chmura et al., 2021) .
115 Currently, neoadjuvant radiotherapy can be applicable for inoperable breast cancer to
116 allow an effective and sometimes more conservative surgery(Cardoso et al., 2018) .
117 Preclinical studies have indicated that CDK4/6 inhibitors can sensitize breast cancer
118 cells to radiotherapy, possibly by inhibition of DNA damage repair response,
119 enhancement of apoptosis and blockage of cell cycle progression, and inhibition of
120 intra-tumor cellular metabolism and angiogenesis (Han et al., 2013; A. M. Pesch et al.,
121 2020; G. Petroni et al., 2021) . A preclinical study has explored different schedules of
122 combination of radiotherapy and CDK4/6 inhibitors in human and mouse model and
123 demonstrated that radiotherapy followed by CDK4/6 inhibitors can enhance
124 antineoplastic effects, compared with their monotherapy alone or CDK4/6 inhibitors

125 concurrent with or followed by radiotherapy (G. Petroni et al., 2021) . Moreover, the
126 combination of CDK4/6 inhibitors and radiotherapy can lead to a satisfying overall
127 disease control and safety based on several retrospective studies in metastatic breast
128 cancer (Bosacki et al., 2021) . Nevertheless, the efficacy and safety of this regimen in
129 neoadjuvant treatment of early-stage HR-positive, HER2-negative breast cancer are
130 unknown.

131 We have conducted a prospective pilot study to determine the efficacy and safety of
132 neoadjuvant radiotherapy followed by dalpiciclib and exemestane in patients with
133 newly-diagnosed early or locally advanced HR-positive, HER2-negative breast cancer.
134 Dalpiciclib (SHR6390) is a potent selective inhibitor of CDK4/6 and exerts
135 synergistic anti-tumor effect when combined with endocrine therapy for advanced
136 luminal breast cancer in the DAWNA-1 trials (Xu et al., 2021) .

137

138 **Methods**

139 **Study design**

140 This single-arm, non-controlled prospective pilot study in women with HR-positive,
141 HER2-negative early or locally advanced breast cancer was registered with
142 ClinicalTrials.gov (NCT05132790).

143 The study was approved by the Institutional Review Board and Ethics Committee of
144 Shengjing Hospital of China Medical University, according to the Declaration of
145 Helsinki and Good Clinical Practice guidelines. Written informed consent was

146 obtained from each patient.

147

148 **Participants**

149 Eligible patients included pre- and post-menopausal women aged between 18 and 75
150 years, with histologically confirmed HR-positive, HER2-negative (0 or 1+ by
151 immunohistochemistry [IHC], or 2+ by IHC with negative results of fluorescence in
152 situ hybridization) invasive breast cancer at stage II-III with the lesion of ≥ 2 cm by
153 MRI. Other main inclusion criteria were Eastern Cooperative Oncology Group
154 performance status 0-1, adequate marrow, hepatic and renal function. The key
155 exclusion criteria included stage IV tumors, inflammatory breast cancer, prior
156 systemic treatment of the current cancer, other malignancies, cardiac disease or
157 history of cardiac dysfunction, pregnancy, lactation, and refusal to use contraception.

158

159 **Procedures**

160 SBRT was performed every other day in breast target lesion with a total radiation
161 dose of 24Gy separated by 3 fractions. Within 2-4 weeks after the completion of
162 radiotherapy, individual patients received 6 cycles of combination of oral 150 mg
163 Dalpiciclib daily on days 1-21 of each 4-week cycle and 25 mg exemestane with a
164 total duration of 24 weeks. Patients without menopause were also injected
165 subcutaneously with 3.6 mg goserelin every 4 weeks. All patients received study
166 treatment until completion of all prescribed protocol therapy, disease progression,

167 unacceptable toxicity, or withdrawal of consent. If disease progression, the patient
168 was either proceed to surgery or received alternative neoadjuvant therapy. Surgery
169 was performed 3-5 weeks after the last dose of dalpiciclib to allow adverse event (AE)
170 recovery. Recommended surgery and adjuvant therapy followed per local guidelines
171 or institutional standards. The necessity of additional chemotherapy for patients with
172 pCR was judged by investigators.

173

174 **Outcomes**

175 The primary endpoint was the rate of residual cancer burden (RCB) 0-I. Secondary
176 endpoints included ORR (defined as the proportion of patients with complete or
177 partial response according to the Response Evaluation Criteria In Solid Tumors
178 [RECIST] version 1.1 by MRI), pCR rate in the breast and axillary lymph nodes
179 (tpCR; ypT0/is ypN0) and in the breast (bpCR; ypT0/is ypNx), preoperative
180 endocrine prognostic index (PEPI) score for breast cancer-specific survival (BCSS)
181 (PEPI 0), and safety, according to the Common Terminology Criteria for Adverse
182 Events (CTCAE) version 5.0.

183

184 **Patient-Reported Outcome (PRO) assessments**

185 In the study, the patient-reported outcome (PRO) assessments was measured using the
186 European Organization for Research and Treatment of Cancer (EORTC) Quality of
187 Life Questionnaire Core-30 (QLQ-C30; version 3) (Cull, 1998) at baseline, at the end

188 of cycles 1 to 6, and before surgery. The PRO data were scored, according to the
189 EORTC scoring manual. A raw score was calculated as the average of items
190 contributing to a scale and standardized to a range of 0 to 100 points. On global health
191 status and functioning scales, a higher score indicated better status. Higher scores on
192 symptom scales indicated worse symptoms.

193

194 **Tumor-infiltrating lymphocytes (TILs)**

195 Tumor samples were collected when performing needle biopsy and surgery. The
196 specimens were fixed in 10% formalin and paraffin-embedded. The tissue sections (3
197 μm) were stained with hematoxylin and eosin (H&E) and the frequency of TILs were
198 quantified manually by a pathologist in a blinded manner. The TILs scores were
199 determined as the percentage of TILs in tumor area (tumor cells and stroma). The
200 percentage of stromal TILs (sTILs) was calculated in accordance with the
201 recommendations by an International TILs Working Group 2014 (Salgado et al.,
202 2015) .

203

204 **Programmed cell death-ligand 1 (PD-L1) expression**

205 The expression of programmed cell death-ligand 1 (PD-L1) was characterized by
206 immunohistochemistry (IHC) using anti-PD-L1 (clone SP142, Spring Bioscience,
207 USA) and the percentages of PD-L1 positive tumor cells (TC) or infiltrating
208 inflammatory cells (IC) were quantified.

209

210 **Statistical analysis**

211 All statistical analyses were conducted using SAS 9.4 (North Carolina, USA).

212 Continuous data are presented as mean and standard deviation (SD) or mean and 95%

213 confidence interval (CI). Categorical data are expressed as frequency and percentage.

214 The 95% CIs of pathological complete response rate, proportion of patients with

215 RCB-0 or RCB-I, and ORR were estimated using the Clopper-Pearson method.

216

217 **Results**

218 **Patient characteristics**

219 Between November 2021 and January 2022, 12 HR-positive, HER2-negative patients

220 were screened and recruited in the trial. Their baseline demographic and clinical

221 characteristics are shown in **Table 1**. They had a median age of 48.5 years (range, 36-

222 56) and the median tumor size of 33.5mm (range, 23-90) assessed by breast MRI.

223

224 **Patient outcomes**

225 After the completion of study treatment, 2 (16.7%, 95% CI 3.5%-46.0%) out of 12

226 patients achieved RCB 0–I tumor response, tpCR and PEPI 0 (**Table 2**). There were 3

227 (25.0%) patients reached bpCR. Overall, this study led to an ORR (as assessed by

228 breast MRI) of 91.7% (95% CI 62.5%-100%, **Fig. 1**). Rate of conversion from

229 mastectomy at baseline to breast conservation at surgery was 25.0% (95% CI 8.3%-

230 53.9%). The median Ki67 of surgical specimens for patients without pCR was 7%
231 (range, 5-70).

232

233 **Toxicity**

234 All patients completed the study treatment and AEs are summarized in **Table 3**. The
235 most frequent grade 1-2 AEs were leukopenia (58.3%), hot flushes (50.0%) and
236 lymphopenia (50.0%). There were some patients with Grade 3 AEs, including
237 neutropenia (66.7%) and leukopenia (25.0%), but not grade 4 AEs. There was no
238 serious AEs, no therapy-related death and no patients with dose interruption and
239 reduction or treatment discontinuation in this population. Furthermore, there was no
240 patient with radiation-related dermatitis and skin hyperpigmentation in this population.

241

242 **Patient-reported outcome**

243 All patients completed the EORTC QLQ-C30 and had available results of PRO
244 assessment (**Fig. 2**). There was no clinically significant deterioration in global health
245 status, physical, role, emotional, cognitive and social functioning in this population.

246

247 **Alteration in tumor immune microenvironment**

248 To examine the impact of this new neoadjuvant therapy on tumor environment, we
249 performed H&E staining of tissue sections in 10 evaluable patients (**Fig. 3**).
250 Compared with those in pre-treatment biopsied tissues, treatment significantly

251 increased the percentages of tumor-infiltrating lymphocytes (TILs) in the tumor
252 environment (22.9% vs.10.7%, P=0.043). IHC staining of PD-L1 revealed that there
253 appeared no significant difference in the percent of PD-L1 positive immune cells and
254 tumor cells between the pre-treatment and post-treatment specimens.

255

256 **Discussion**

257 This pioneering study reported the efficacy and safety of sequential neoadjuvant
258 radiotherapy and combination of dalpiciclib and exemestane in patients with HR-
259 positive, HER2-negative breast cancer. This new therapeutic regimen achieved
260 considerable anti-tumor activity with the RCB 0-I rate of 16.7% and ORR rate of
261 91.7%, respectively. More importantly, this combinatory therapeutic strategy was
262 well tolerated in this population

263 CDK4/6 inhibitors have recently been preclinically identified as radiosensitizers,
264 acting mainly through hindering DNA damage repair response after radiation
265 exposure, and enhancing cell apoptosis and blocking cell cycle, which provide a
266 conceptual basis of combining radiotherapy with a CDK4/6 inhibitor (Khasraw et al.,
267 2017; Xie et al., 2019). Moreover, both radiotherapy and CDK4/6 inhibitors exert
268 immunomodulatory effects and may synergize anticancer immune responses(Andrea
269 M Pesch et al., 2020). SBRT with hypofractionation and higher radiation doses is
270 more effective than conventional fractionation in triggering immune
271 responses(Gandhi et al., 2015). Consistent with the basic research(Giulia Petroni et

272 al., 2021), we used the sequential treatment with SBRT and combination of
273 dalpiciclib and exemestane.

274 Unlike HER2-positive and triple-negative breast cancer, NCT or NET for HR-positive,
275 HER2-negative breast cancer only achieves a pCR rate of $\leq 10\%$ (Cortazar et al.,
276 2014) . Our study indicated that this novel therapeutic regiment achieved a pCR and
277 RCB 0-I rate of 16.7% , while neoadjuvant therapies with combination of a CDK4/6
278 inhibitor and letrozole led to a pCR rate of 0-3.8% and RCB 0-I rate of 6.1-7.7% and
279 treatment with NCT resulted in a pCR rate of 5.8-5.9% and RCB 0-I rate of 11.8-15.7%
280 in HR-positive, HER2-negative breast cancer patients(C. X. Ma et al., 2017; Prat et al.,
281 2020). It is notable that pCR rate (commonly defined as ypT0/isN0) is not
282 significantly associated with the prognosis of HR-positive, HER2-negative breast
283 cancer(Cynthia X Ma et al., 2017). In addition, clinical trials to test different therapies
284 for patients with HR-positive, HER2-negative breast cancer have focused on clinical
285 response rates as important clinical endpoints. (Hurvitz et al., 2020; Johnston et al.,
286 2019; Khan et al., 2020; Khasraw et al., 2017; C. X. Ma et al., 2017) In our study,
287 treatment with the new therapeutic regiment led to eleven (91.7%) patients achieving
288 objective responses by MRI, while previous studies have revealed that NET achieves
289 an objective response rate of approximately 60% in HR-positive, HER2-negative
290 breast cancer patients. (Sella et al., 2021) With the addition of SBRT, a slightly higher
291 rate of patients changed from mastectomy to breast conservation compared with
292 PALLET study (25.0% vs 14.1%). (Johnston et al., 2019) Therefore, our new

293 neoadjuvant therapeutic regiment appeared to improve the likelihood of pathological
294 downstaging and achieve a margin-free resection, particularly for those with locally
295 advanced and high-risk breast cancer.

296 Considering that treatment with radiotherapy or a CDK4/6 inhibitor can enhance anti-
297 tumor immunity in vitro, We analyzed the impact of new neoadjuvant therapeutic
298 regiment on alternation in biomarker expression in the numbers of TILs before and
299 after the treatment., Our study showed a modest but statistically significant increase in
300 the tumor tissues with the addition of SBRT. Apparently, sequential neoadjuvant
301 therapies with radiotherapy, a CDK 4/6 inhibitor and exemestane turned non-
302 responsive ‘cold’ tumors into responsive ‘hot’ ones. Therefore, our findings may
303 provide significant insights into designing effective therapeutic strategies against HR-
304 positive, HER2-negative breast cancer.

305 Patients with HR-positive, HER2-negative breast cancer were well-tolerated to the
306 combinational regimen. During the observation period, those patients only developed
307 grade 1-3 of AEs, including grade 3 neutropenia (66.7%), similar to that of
308 combination of dalpiciclib and fulvestrant in the DAWNA-1 trial (84.2%). (Xu et al.,
309 2021) There was no new AEs following therapies with radiotherapy and dalpiciclib in
310 this population.

311 We recognized that our study had limitations, including a one-arm preliminary
312 exploratory trial with small sample size. The small sample size limited the comparison
313 of our data with historical data in the literature due to the potential bias. Thus, further

314 prospective randomized clinical trials with a larger population for longer treatment

315 duration are warranted to validate the findings.

316 In conclusion, our study provides novel insights into the neoadjuvant treatment of

317 HR+/HER2- breast cancer. The sequential radiotherapy and a CDK4/6 inhibitor plus

318 ET is feasible as neoadjuvant therapy for HR-positive, HER2 -negative breast cancers.

319 This neoadjuvant regimen was effective and well-tolerated, which could serve as a

320 promising alternative regimen in treatment of patients with HR-positive, HER2-

321 negative breast cancer. Further validation of these findings is warranted in a large-

322 scale study.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342 **Acknowledgments**

343 Jiangsu Hengrui Pharmaceuticals provided the study drug dalpiciclib free of charge
344 for patients enrolled in the study. We thank the patients, their families involved in this
345 study.

346

347 **Conflict of interest**

348 Jianfei Wang is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Caigang
349 Liu is a senior editor of eLife. Yongliang Yang is a reviewing editor of eLife. The
350 other authors declare that no competing interests exist.

351 **Funding**

352 This research did not receive any specific grant from funding agencies in the public,
353 commercial, or not-for-profit sectors.

354

355 **Author ORCIDs** : Caigang Liu <https://orcid.org/0000-0003-2083-235X>

356

357 **Data availability statement**

358 The raw clinical and imaging data are protected due to patient privacy laws. The
359 datasets generated and/or analyzed during the current study are available from the
360 corresponding author Caigang Liu on request for 10 years; de-identified clinical data
361 and experimental data are available on request sharing, which will need the approval
362 of the Institutional Ethical Committees. De-identified data will then be transferred to
363 the inquiring investigator over secure file transfer.

364

365 **References**

366 Bosacki, C., Bouleftour, W., Sotton, S., Vallard, A., Daguene, E., Ouaz, H., Cojoracu, I.,
367 Moslemi, D., Molekzadehmoghani, M., & Magné, N. (2021). CDK 4/6 inhibitors
368 combined with radiotherapy: A review of literature. *Clin Transl Radiat Oncol*, *26*, 79-
369 85. <https://doi.org/10.1016/j.ctro.2020.11.010>

370

371 Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N.,
372 Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B.,
373 Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S.,
374 Eniu, A., . . . Winer, E. P. (2018). 4th ESO-ESMO International Consensus Guidelines
375 for Advanced Breast Cancer (ABC 4)†. *Ann Oncol*, *29*(8), 1634-1657.

376 <https://doi.org/10.1093/annonc/mdy192>

377

378 Chmura, S., Winter, K. A., Robinson, C., Pisansky, T. M., Borges, V., Al-Hallaq, H., Matuszak,
379 M., Park, S. S., Yi, S., Hasan, Y., Bazan, J., Wong, P., Yoon, H. A., Horton, J., Gan,
380 G., Milano, M. T., Sigurdson, E. R., Moughan, J., Salama, J. K., & White, J. (2021).
381 Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients
382 With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. *JAMA Oncol*,
383 7(6), 845-852. <https://doi.org/10.1001/jamaoncol.2021.0687>

384

385 Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H.,
386 Cameron, D., Gianni, L., Valagussa, P., Swain, S. M., Prowell, T., Loibl, S.,
387 Wickerham, D. L., Bogaerts, J., Baselga, J., Perou, C., Blumenthal, G., Blohmer,
388 J., . . . von Minckwitz, G. (2014). Pathological complete response and long-term
389 clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 384(9938),
390 164-172. [https://doi.org/10.1016/s0140-6736\(13\)62422-8](https://doi.org/10.1016/s0140-6736(13)62422-8)

391

392 Cox, J. A., & Swanson, T. A. (2013). Current modalities of accelerated partial breast
393 irradiation. *Nat Rev Clin Oncol*, 10(6), 344-356.
394 <https://doi.org/10.1038/nrclinonc.2013.65>

395

396 Cull, A. (1998). EORTC QLQ-30. A breach of copyright. *Int J Pancreatol*, 24(1), 64-65.

397 <https://doi.org/10.1007/bf02787535>

398

399 Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R.,

400 Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C.,

401 Huang, X., Kim, S. T., Randolph, S., & Slamon, D. J. (2015). The cyclin-dependent

402 kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as

403 first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast

404 cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 16(1), 25-

405 35. [https://doi.org/10.1016/s1470-2045\(14\)71159-3](https://doi.org/10.1016/s1470-2045(14)71159-3)

406

407 Gandhi, S. J., Minn, A. J., Vonderheide, R. H., Wherry, E. J., Hahn, S. M., & Maity, A. (2015).

408 Awakening the immune system with radiation: optimal dose and fractionation. *Cancer*

409 *letters*, 368(2), 185-190. [https://doi: 10.1016/j.canlet.2015.03.024](https://doi:10.1016/j.canlet.2015.03.024).

410

411 Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H.,

412 Trédan, O., Chen, S. C., Manso, L., Freedman, O. C., Garnica Jaliffe, G., Forrester,

413 T., Frenzel, M., Barriga, S., Smith, I. C., Bourayou, N., & Di Leo, A. (2017).

414 MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin*

415 *Oncol*, 35(32), 3638-3646. <https://doi.org/10.1200/jco.2017.75.6155>

416

417 Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B.,
418 Burstein, H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P.,
419 Goldstein, L. J., Hurvitz, S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H.,
420 Krishnamurthy, J., . . . Kumar, R. (2022). Breast Cancer, Version 3.2022, NCCN
421 Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 20(6), 691-722.
422 <https://doi.org/10.6004/jnccn.2022.0030>

423

424 Han, Y. K., Lee, J. H., Park, G. Y., Chun, S. H., Han, J. Y., Kim, S. D., Lee, J., Lee, C. W.,
425 Yang, K., & Lee, C. G. (2013). A possible usage of a CDK4 inhibitor for breast cancer
426 stem cell-targeted therapy. *Biochem Biophys Res Commun*, 430(4), 1329-1333.
427 <https://doi.org/10.1016/j.bbrc.2012.10.119>

428

429 Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S.,
430 Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte,
431 P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan,
432 A., . . . O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive,
433 Advanced Breast Cancer. *N Engl J Med*, 375(18), 1738-1748.
434 <https://doi.org/10.1056/NEJMoa1609709>

435

436 Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer,
437 R., Guarneri, V., Huang, C. S., Barriga, S., Wijayawardana, S., Brahmachary, M.,
438 Ebert, P. J., Hossain, A., Liu, J., Abel, A., Aggarwal, A., Jansen, V. M., & Slamon, D.
439 J. (2020). Potent Cell-Cycle Inhibition and Upregulation of Immune Response with
440 Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in
441 HR(+)/HER2(-) Breast Cancer. *Clin Cancer Res*, 26(3), 566-580.
442 <https://doi.org/10.1158/1078-0432.CCR-19-1425>
443
444 Johnston, S., Puhalla, S., Wheatley, D., Ring, A., Barry, P., Holcombe, C., Boileau, J. F.,
445 Provencher, L., Robidoux, A., Rimawi, M., McIntosh, S. A., Shalaby, I., Stein, R. C.,
446 Thirlwell, M., Dolling, D., Morden, J., Snowdon, C., Perry, S., Cornman, C., . . .
447 Jacobs, S. A. (2019). Randomized Phase II Study Evaluating Palbociclib in Addition
448 to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast
449 Cancer: PALLET Trial. *J Clin Oncol*, 37(3), 178-189.
450 <https://doi.org/10.1200/jco.18.01624>
451
452 Khan, Q. J., O'Dea, A., Bardia, A., Kalinsky, K., Wisinski, K. B., O'Regan, R., Yuan, Y., Ma, C.
453 X., Jahanzeb, M., Trivedi, M. S., Spring, L., Makhoul, I., Wagner, J. L., Winblad, O.,
454 Amin, A. L., Blau, S., Crane, G. J., Elia, M., Hard, M., & Sharma, P. (2020). Letrozole
455 + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer

456 (FELINE trial). *Journal of Clinical Oncology*, 38(15_suppl), 505-505.

457 https://doi.org/10.1200/JCO.2020.38.15_suppl.505

458

459 Khasraw, M., Chung, S., Day, B., Johns, T., Joshi, S., Madani, D., McDonald, K., & Whittaker,

460 S. (2017). Combination of palbociclib and radiotherapy for glioblastoma. *Cell Death*

461 *Discov* 2017;3:17033. <https://doi: 10.1038/cddiscovery.2017.33>.

462

463 Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M.,

464 Ademuyiwa, F., Suresh, R., Anderson, K. S., Margenthaler, J., Aft, R., Hobday, T.,

465 Moynihan, T., Gillanders, W., Cyr, A., Eberlein, T. J., Hieken, T., . . . Ellis, M. J.

466 (2017). NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor,

467 and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

468 *Clin Cancer Res*, 23(15), 4055-4065. <https://doi.org/10.1158/1078-0432.Ccr-16-3206>

469

470 Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., Davies, S.,

471 Fauron, C., He, X., Hu, Z., Quackenbush, J. F., Stijleman, I. J., Palazzo, J., Marron, J.

472 S., Nobel, A. B., Mardis, E., Nielsen, T. O., Ellis, M. J., Perou, C. M., & Bernard, P. S.

473 (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin*

474 *Oncol*, 27(8), 1160-1167. <https://doi.org/10.1200/jco.2008.18.1370>

475

- 476 Pesch, A. M., Hirsh, N. H., Chandler, B. C., Michmerhuizen, A. R., Ritter, C. L., Androsiglio, M.
477 P., Wilder-Romans, K., Liu, M., Gersch, C. L., Larios, J. M., Pierce, L. J., Rae, J. M.,
478 & Speers, C. W. (2020). Short-term CDK4/6 Inhibition Radiosensitizes Estrogen
479 Receptor-Positive Breast Cancers. *Clin Cancer Res*, 26(24), 6568-6580.
480 <https://doi.org/10.1158/1078-0432.Ccr-20-2269>
481
482 Petroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen-Kiang, S., Formenti, S. C.,
483 & Galluzzi, L. (2021). Radiotherapy Delivered before CDK4/6 Inhibitors Mediates
484 Superior Therapeutic Effects in ER(+) Breast Cancer. *Clin Cancer Res*, 27(7), 1855-
485 1863. <https://doi.org/10.1158/1078-0432.Ccr-20-3871>
486
487 Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., Farré, B. G., Fernández,
488 P. L., Galván, P., & Chic, N. (2020). Ribociclib plus letrozole versus chemotherapy for
489 postmenopausal women with hormone receptor-positive, HER2-negative, luminal B
490 breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
491 *The lancet oncology*, 21(1), 33-43. [https://doi: 10.1016/s1470-2045\(19\)30786-7](https://doi:10.1016/s1470-2045(19)30786-7).
492
493 Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S.,
494 Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E.
495 A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis,

496 M., Floris, G., . . . Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes
497 (TILs) in breast cancer: recommendations by an International TILs Working Group
498 2014. *Ann Oncol*, 26(2), 259-271. <https://doi.org/10.1093/annonc/mdu450>
499
500 Sella, T., Weiss, A., Mittendorf, E. A., King, T. A., Pilewskie, M., Giuliano, A. E., & Metzger-
501 Filho, O. (2021). Neoadjuvant Endocrine Therapy in Clinical Practice: A Review.
502 *JAMA Oncol*, 7(11), 1700-1708. <https://doi.org/10.1001/jamaoncol.2021.2132>
503
504 Xie, X., Zheng, W., Chen, T., Lin, W., Liao, Z., Liu, J., & Ding, Y. (2019). CDK4/6 inhibitor
505 palbociclib amplifies the radiosensitivity to nasopharyngeal carcinoma cells via
506 mediating apoptosis and suppressing DNA damage repair. *Oncotargets and therapy*,
507 11107-11117. [https://doi: 10.2147/ott.S234221](https://doi:10.2147/ott.S234221).
508
509 Xu, B., Zhang, Q., Zhang, P., Hu, X., Li, W., Tong, Z., Sun, T., Teng, Y., Wu, X., Ouyang, Q.,
510 Yan, X., Cheng, J., Liu, Q., Feng, J., Wang, X., Yin, Y., Shi, Y., Pan, Y., Wang, Y., . . .
511 Zou, J. (2021). Dapiciclib or placebo plus fulvestrant in hormone receptor-positive
512 and HER2-negative advanced breast cancer: a randomized, phase 3 trial. *Nat Med*,
513 27(11), 1904-1909. <https://doi.org/10.1038/s41591-021-01562-9>
514
515

516 **Table 1: Baseline characteristics of the patients.**

	Patients (n=12)
Median age (range), years	48.5 (36-56)
≤ 50	6 (50.0%)
> 50	6 (50.0%)
Menopausal status	
Premenopausal	6 (50.0%)
Postmenopausal	6 (50.0%)
Tumor size	
T2	11 (91.7%)
T3	1 (8.3%)
Lymph node status	
N0	5 (41.7%)
N1	2 (16.7%)
N2	5 (41.7%)
Clinical stage	
IIA	4 (33.3%)
IIB	3 (25.0%)
IIIA	5 (41.7%)
Tumor grade	
II	11 (91.7%)
III	1 (8.3%)
ER expression	
> 10%	12 (100.0%)
PgR expression	
< 20%	3 (25.0%)
≥ 20%	9 (75.0%)
HER2 expression	
Negative	7 (58.3%)
1+	1 (8.3%)
2+, FISH	4 (33.3%)
Median baseline Ki67 (range), %	35 (15-70)
≤ 14%	3 (25.0%)
> 14%	9 (75.0%)

Data are n (%) or median (range).

ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth

factor receptor 2; FISH: fluorescence in situ hybridization.

517 **Table 2: Pathological and clinical response (n=12).**

	n (%)
Total pathological complete response	2 (16.7%)
Breast pathological complete response	3 (25.0%)
Residual cancer burden score	
0	2 (16.7%)
I	0
II	6 (50.0%)
III	4 (33.3%)
Radiological response	
Complete response	2 (16.7%)
Partial response	9 (75.0%)
Stable disease	1 (8.3%)
Objective response rate	11 (91.7%)
Preoperative endocrine prognostic index	
0	2 (16.7%)
1-3	0
≥4	10 (83.3%)

Data are presented as n (%)

518

519

520

521 **Table 3: Treatment-emergent adverse events (n=12).**

	n (%)		
	Grade 1 or 2	Grade 3	Grade 4
Neutropenia	3 (25.0%)	8 (66.7%)	0
Leukopenia	7 (58.3%)	3 (25.0%)	0
Hot flushes	6 (50.0%)	0	0
Lymphopenia	6 (50.0%)	0	0
Insomnia	4 (33.3%)	0	0
Alopecia	4 (33.3%)	0	0
Anemia	4 (33.3%)	0	0
Hyperuricemia	4 (33.3%)	0	0
Blood urea increased	4 (33.3%)	0	0
Rash	3 (25.0%)	0	0
Thrombocytopenia	3 (25.0%)	0	0
Hyperglycemia	3 (25.0%)	0	0
Creatinine increased	3 (25.0%)	0	0
Fatigue	3 (25.0%)	0	0
Arthralgia	2 (16.7%)	0	0
γ-glutamyl transferase increased	2 (16.7%)	0	0
Hypocalcemia	2 (16.7%)	0	0
Abnormal T wave of electrocardiogram	2 (16.7%)	0	0
Hyponatremia	2 (16.7%)	0	0
Lactate dehydrogenase increased	2 (16.7%)	0	0
Diarrhea	1 (8.3%)	0	0
Headache	1 (8.3%)	0	0
Mucosal inflammation Constipation	1 (8.3%)	0	0
Proteinuria	1 (8.3%)	0	0
Hypertriglyceridemia	1 (8.3%)	0	0
Alanine aminotransferase increased	1 (8.3%)	0	0

Data are presented as n (%).

522

523

524 **Figure legends**

525

526 **Figure 1:** Waterfall plot of best reduction in tumor measurement from baseline.

527 **Figure 2:** Mean change from baseline in QLQ-C30 over time. (A) Global health

528 status. (B-F) Physical, role, emotional, cognitive and social functioning.


529 **Figure 3:** TILs and PD-L1 changes before and after treatment. (A) Study schema. (B)

530 Representative TILs. Scale bar, 100 μ M. (C-E) Percentage of TILs, PD-L1 expression

531 in immune cell and tumor cell in paired specimens (n=10). Bars, boxes, and whiskers

532 represent median, interquartile range, and range, respectively.

533



SBRT-Dalpiciclib+Exemestane

